ProPublica: Clear Labels Act Stripped of Drug Safety Provisions

Legislation designed to reveal the manufacturing origins of medications is heading for a full Senate vote after lawmakers stripped out key safety provisions, including a unique tracking code and a one-year compliance timeline, according to policy experts and legislative documents. Rick Scott, R-Fla., and Kirsten Gillibrand, D-N.Y., aims to let doctors and patients see exactly where drugs are made, following a ProPublica investigation revealing the U.S. imported generic drugs from foreign factories cited for quality and safety lapses like mold and contaminated water.

Watered-Down Provisions Spark Criticism From Safety Experts

Lawmakers removed a requirement for labels to include the Food and Drug Administration’s unique facility identification number, known as a DUNS number, which allows researchers to easily track regulatory histories. According to retired Army Col. Vic Suarez, a former medical supply-chain commander, the changes represent a clear watering down of the original bill. Stanford University professor of medicine Dr. Kevin Schulman criticized the decision to extend the compliance timeline from one year to five years, stating that five years after passage might as well be a lifetime.

Scott and Gillibrand praised the bill’s progress as a massive win for consumer safety and transparency, though they did not address the modifications. A representative from Gillibrand’s office explained that the five-year delay provides the FDA time for rulemaking and allows manufacturers time to redesign labels. However, former FDA inspector Peter Baker questioned the extended timeline, noting that updating labels is a simple process that could be accomplished in a year if desired.

Address Loopholes and Enforcement Challenges

Under the updated legislative language, drug labels will only need to show a factory address rather than a precise facility identification number. Ohio State University professor John Gray testified before the Senate Special Committee on Aging that vague phrasing allowing a place of business could let manufacturers list corporate headquarters or importer locations in the United States instead of overseas factories. According to Baker, this flexibility places an unnecessary burden on overworked inspectors trying to verify compliance.

Did You Know? ProPublica’s Rx Inspector tool used unique facility identification numbers to connect generic drug labels to specific manufacturing sites in 69% of prescription drug labels reviewed during their investigation.

Industry Pushback and Legislative Pathway

The legislation faced opposition during committee deliberations from lawmakers concerned about national security and production hurdles. Sen. Maggie Hassan, D-N.H., raised security worries regarding precise facility locations, while Sen. Rand Paul, R-K.Y., dissented over potential regulatory burdens. Despite these objections, the revised bill passed the Senate Committee on Health, Education, Labor and Pensions in July with only Paul voting against it.

The Association for Accessible Medicines, a generic drug lobbying group, did not respond to requests for comment regarding the bill. Public filings show the trade group spent over $1 million between January and July on healthcare and generics-related bills. A date for the full Senate vote has not yet been scheduled.

Frequently Asked Questions

What is the Clear Labels Act?

Rick Scott and Kirsten Gillibrand designed to inform consumers and doctors about the exact manufacturing locations of their medications.

ProPublica: Clear Labels Act Stripped of Drug Safety Provisions
Photo: cmio.org

Why were provisions removed from the bill?

People familiar with legislative deliberations indicated that lawmakers worried strict requirements would raise drug prices and expose sensitive locations of lifesaving medications, leading to compromises that removed the unique identifier and extended compliance timelines.

What replaces the unique facility identification number on labels?

The updated version of the legislation requires manufacturers to list a physical address, though safety experts warn that ambiguous phrasing could permit companies to list domestic headquarters instead of foreign production facilities.

Stay Informed on Healthcare Policy

Subscribe to our newsletter to receive updates on federal legislation, drug safety investigations, and pharmaceutical supply chain developments.

Subscribe Now

Leave a Comment